Results 221 to 230 of about 114,065 (338)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321. [PDF]

Br J Haematol
Yi S, Cao J, Feng R, Zhou K, Qiu L, Li F, Yang HY, Zhou H, Hui W, Cui J, Huang H, Zhu J, Ye X, Sharman J, Qiu L.   +14 more
europepmc   +1 more source

Oral Angiolymphoid Hyperplasia With Eosinophilia Exhibiting Cutaneous‐Type Histopathologic Features: Clinical Regression Following Hormonal Withdrawal and a 50‐Year Review

Journal of Cutaneous Pathology, EarlyView.
Case report of a 30‐year‐old female. Asymptomatic, red‐purple hyperplastic lesion extending from teeth 21 to 25, with bleeding upon manipulation. Differential diagnosis included: inflammatory gingival hyperplasia, plasma cell gingivitis, leukemia, and Wegener's granulomatosis.
Pedro Vinícius Santos de Jesus, Louise Cristina Santos, Gilberth Tadeu Dos Santos Aciole, John Lennon Silva Cunha, Nicole Lonni, Matheus Antoni da Silva Costa, Elena Riet Correa Rivero, Rogério Gondak, Ricardo Luíz Cavalcanti de Albuquerque‐Júnior   +8 more
wiley   +1 more source

Re-emergence of circulating non-malignant B cells as a prognostic biomarker in chronic lymphocytic leukaemia. [PDF]

Sci Rep
Lim YJ, Duckworth A, Clarke K, Oates M, Karpha I, Gornall M, Kalakonda N, Slupsky J, Pettitt A.   +8 more
europepmc   +1 more source

Eccrine Squamous Syringometaplasia Mimicking Acute Cutaneous GVHD in a Pediatric HSCT Recipient: Case Report and Brief Review of the Indexed Literature

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Eccrine squamous syringometaplasia (ESS) is an uncommon reactive alteration of eccrine ducts, most often reported in oncologic and transplant settings, where it may clinically mimic acute cutaneous graft‐versus‐host disease (GVHD). We describe a 3‐year‐old boy with chronic granulomatous disease who developed a diffuse erythematous eruption 6 ...
Benedetta Galli, Cecilia Catapano, Iacopo Ghini, Mariateresa Rossi, Marina Venturini, Valeria Boccaletti   +5 more
wiley   +1 more source

Matching-adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed-duration venetoclax and ibrutinib in patients with treatment-naïve chronic lymphocytic leukaemia. [PDF]

Br J Haematol
Munir T, Mohseninejad L, Rakonczai P, Dobi B, Xu S, Yang K, Vezan R, Calle NM.   +7 more
europepmc   +1 more source

HAT‐PCR is non‐inferior to NGS when quantifying measurable residual disease for myeloma

British Journal of Haematology, EarlyView.
Elizabeth Hughes, Piers Blombery, Sushmitha Kannan, Tiffany Khong, Andrew Spencer, Alexander Morley   +5 more
wiley   +1 more source

A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Cutaneous extramedullary hematopoiesis (CEH) is a rare manifestation of extramedullary hematopoiesis (EMH), a process typically associated with fetal development or myeloproliferative neoplasms. EMH most commonly involves the spleen, liver, and lymph nodes, with CEH being exceedingly rare in chronic myeloid leukemia (CML).
Bennett Christie‐Nguyen, Hanadi El Achi, Levani Iashvili, Amer Wahed, Brenda Mai, Jacob Armstrong   +5 more
wiley   +1 more source

Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era. [PDF]

Intern Med J
Barge L, Tran S, Kennedy G, Ritchie D, Gottlieb D, Milliken S, Spencer A, Purtill D, Perera T, Doocey R, Larsen S, Butler A, Bardy P, Greenwood M, Durrant S, Curley C, Stewart C, Tam C, Balendran S, Di Ciaccio PR, Patil S, Han MH, Hamad N.   +22 more
europepmc   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source